s0122320
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.300
- ESTROGEN_RESPONSE_EARLY+0.200
- PROTEIN_SECRETION+0.200
- ANDROGEN_RESPONSE+0.100
- APICAL_SURFACE+0.100
- BILE_ACID_METABOLISM+0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.100
- ESTROGEN_RESPONSE_LATE+0.100
- KRAS_SIGNALING_DN+0.100
- APICAL_JUNCTION+0.000
Top 10 suppressed
- MTORC1_SIGNALING-0.500
- ALLOGRAFT_REJECTION-0.400
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- MYC_TARGETS_V1-0.400
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- UV_RESPONSE_UP-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518182 | — | C | 0.870 |
| 2 | TCGA-D8-A73X-01A-11R-A32P-07 | — | B | 0.862 |
| 3 | C3L-02958 | — | cohortA1 | 0.852 |
| 4 | SRR8613714 | — | A | 0.850 |
| 5 | TCGA-J2-A4AD-01A-11R-A24H-07 | — | cohortA1 | 0.850 |
| 6 | SRR821581 | GTEX | — | 0.849 |
| 7 | SRR8613701 | — | A | 0.848 |
| 8 | AUR-AFUN-TTP1-A-1-0-R-A741-41 | — | D | 0.847 |
| 9 | SRR33532757 | — | A | 0.844 |
| 10 | BS_0Y66ZBWE | low-grade glioma | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |